Sensyne Health PLC Notice of Interim Results (1561L)
January 11 2021 - 1:00AM
UK Regulatory
TIDMSENS
RNS Number : 1561L
Sensyne Health PLC
11 January 2021
Notice of Interim Results
Oxford, UK; 11 January 2021: Sensyne Health plc (LSE: SENS)
("Sensyne" or the "Company") , the Clinical AI company, will
announce its Interim Results for the 6 months ended 31 October 2020
on Thursday 21 January 2021.
Lord (Paul) Drayson, Chief Executive Officer, and Michael
Norris, Interim Chief Financial Officer, will host a virtual
briefing for analysts and investors at 13:00 GMT on the day of the
results.
Details of the webcast, and the presentation slides, will be
available via the Company website. For more details please contact
CSCSensynehealth@consilium-comms.com.
-ENDS-
For more information please contact:
Sensyne Health ( www.sensynehealth.com +44 (0) 330 058
) 1845
Lord (Paul) Drayson PhD FREng, Chief Executive
Officer
Michael Norris, Interim Chief Financial
Officer
Dr Richard Pye, Chief Investment Officer
Peel Hunt LLP (Nominated Adviser and Joint + 44 (0) 20 7418
Broker) 8900
Dr Christopher Golden
James Steel
Oliver Jackson
+ 44 (0) 20 3100
Liberum (Joint Broker) 2000
Bidhi Bhoma
Euan Brown
Consilium Strategic Communications +44 (0) 7780600290
Mary-Jane Elliott
Sukaina Virji
Davide Salvi
CSCSensynehealth@consilium-comms.com
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in
partnership with global healthcare organisations to improve patient
care and accelerate the discovery and development of new medicines.
Sensyne Health is listed on the AIM Market of the London Stock
Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORSFFFMSEFSEIF
(END) Dow Jones Newswires
January 11, 2021 02:00 ET (07:00 GMT)
Sensyne Health (LSE:SENS)
Historical Stock Chart
From Apr 2024 to May 2024
Sensyne Health (LSE:SENS)
Historical Stock Chart
From May 2023 to May 2024